CTLA4 and neoplasm: Lorigerlimab (MGD019) is a bispecific Fc-bearing (IgG4) (dual-affinity re-targeting molecule) DART molecule designed to enhance CTLA-4 blockade on tumor infiltrating lymphocytes, while maintaining maximal PD-1 blockade on PD-1 expressing cells.